Impax Labs announced (in a press release Here) that from July 1, 2009, Impax Pharma, the Company’s specialty brand products division will co-promote Wyeth’s Pristiq®. Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq® (Desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI) as a treatment for adult patients with major depressive disorder (MDD).
As previously announced, Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.
As previously announced, Impax Laboratories entered into a three-year co-promotion agreement with Wyeth in July 2008 to detail a product then to-be named by Wyeth for neurologists. Impax will receive a fee for each detail delivered. Other terms of this agreement are confidential and were not disclosed.
Desvenlafaxine succinate , which is chemically (4-[2-dimethylamino-1-(1-hydroxycyclohexyl) ethyl]phenol is Serotonin/Norepinephrine reuptake inhibitor (antidepressant). Desvenlafaxine succinate is an active metabolite of Venlafaxine (Effexor).
No comments:
Post a Comment